VolitionRX Enhances Veterinary Cancer Detection with Automated Nu.Q® Vet Cancer Test Collaboration

VolitionRX Drives Veterinary Cancer Detection Forward with Automation

VolitionRX Limited, a pioneering company specializing in epigenetics, announces a major advancement in veterinary healthcare following the successful validation and verification of its chemiluminescent immunoassay (ChLIA) version of the Nu.Q® Vet Cancer Test. This breakthrough, achieved in collaboration with Fujifilm Vet Systems Co. Ltd in Japan, enables the full automation of the testing process within central laboratories, transitioning away from the former reliance on manual plates. This technological leap is designed to enhance the efficiency and accessibility of cancer screening for dogs, a critical concern in a nation where an estimated seven million pet dogs reside, and cancer is the leading cause of mortality among adult canines.

The demand for the Nu.Q® Vet Cancer Test has surged since its launch in July 2024, with over 1,700 veterinary hospitals in Japan registering to utilize the test. Fujifilm Vet Systems' President, Junichi Makino, expresses enthusiasm over the central lab automation and its potential to set a new standard in veterinary diagnostics. Given that early detection significantly improves treatment outcomes, the Nu.Q® Vet Cancer Test offers a timely and cost-effective solution for dog owners, thereby addressing an urgent need within the veterinary community.

Dr. Jasmine Kway, CEO of Singapore Volition, underscores the revenue implications of this partnership, pointing out Fujifilm Vet Systems' prominence as a diagnostic provider in Japan's expansive veterinary market. By combining efforts, VolitionRX’s Nu.Q® Vet Cancer Test, which shares technology parallels with human cancer testing modalities, is poised for distribution across Fujifilm’s network of central reference laboratories throughout Japan. This partnership not only streamlines cancer diagnostics for pets but also aligns with VolitionRX's overarching mission to improve health outcomes through advancements in epigenetic research.

In addition to the innovative testing process, the partnership with Fujifilm highlights the broader implications for the veterinary market. The automated features of the Nu.Q® Vet Cancer Test make it a highly sought-after option for veterinary diagnostics, ensuring a quicker turnaround time for test results. This move represents a significant step towards modernizing veterinary medicine and providing veterinarians with better tools to manage canine health.

Furthermore, as the company expands its market presence in Japan, VolitionRX's commitment to enhancing pet healthcare aligns with growing public interest in preventive veterinary medicine. This strategic collaboration sets a foundation for more impactful health solutions that benefit both the veterinary community and pet owners alike, marking a promising future for cancer detection and treatment in animals.